Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
CLEVELAND, April 12, 2018 -- Athersys, Inc. (Nasdaq:ATHX) will release its first quarter 2018 financial results at approximately 4:00 PM Eastern Time on Thursday, May 10, 2018, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the results. Gil Van Bokkelen, Chairman and Chief Executive Officer, and William (B.J.) Lehmann, President and Chief Operating Officer, will host the call as follows:
| Date | May 10, 2018 |
| Time | 4:30 p.m. (Eastern Time) |
| Telephone access: US and Canada | (800) 273-1254 |
| Telephone access: International | (973) 638-3440 |
| Access code | 1189915 |
| Live webcast | www.athersys.com under Investors section |
A replay will be available for on-demand listening shortly after the completion of the call until 11:59 PM Eastern Time on May 24, 2018 at the aforementioned URL, or by dialing (800) 585-8367 or (855) 859-2056 in the U.S. and Canada, or from abroad (404) 537-3406, and entering access code 1189915.
About Athersys
Athersys is an international biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product, initially for disease indications in the neurological, cardiovascular, and inflammatory and immune disease areas, and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and a broad network of collaborations to further advance the MultiStem cell therapy toward commercialization. More information is available at www.athersys.com.
ATHX-G
Contact:
William (B.J.) Lehmann, J.D.
President and Chief Operating Officer
Tel: (216) 431-9900
[email protected]
Karen Hunady
Corporate Communications and Investor Relations
Tel: (216) 431-9900
[email protected]
David Schull
Russo Partners, LLC
Tel: (212) 845-4271 or (858) 717-2310
[email protected]
